Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Lambertini

Showing results (261-270 of 375) with videos related to

Pageof 38
Sort By:
Clinical Breast Cancer|October 20, 2024
Trends and Regional Differences for Fertility Preservation Procedures in Women With Breast CancerVolkan Turan, Giuliano Bedoschi, Dong-Yun Lee, et al.
JCO Precision Oncology|September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease RelapseFrédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
Cancer Treatment Reviews|January 24, 2025
Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussionStavroula L Kastora, Eirini Pantiora, Yong Hwa Hong, et al.
ESMO Open|November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trialMatteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
In Vivo (Athens, Greece)|March 4, 2022
The Margins' Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast CancerPiero Fregatti, Marco Gipponi, Giulia Atzori, et al.
International Journal of Cancer|November 15, 2019
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trialMatteo Lambertini, Francesca Poggio, Marco Bruzzone, et al.
Therapeutic Advances in Medical Oncology|September 22, 2025
Early breast cancer in young <i>BRCA</i> carriers: from diagnosis to treatment and survivorshipRoberto Borea, Luca Arecco, Simone Nardin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2024
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA studyChiara Molinelli, Marco Bruzzone, Eva Blondeaux, et al.
BMC Medicine|January 6, 2016
Cancer and fertility preservation: international recommendations from an expert meetingMatteo Lambertini, Lucia Del Mastro, Maria C Pescio, et al.
Breast (Edinburgh, Scotland)|July 15, 2018
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) studyMatteo Lambertini, Valeria Fontana, Claudia Massarotti, et al.
Pageof 38

Showing results (261-270 of 375) with videos related to

Sort By:
Pageof 38
Clinical Breast Cancer|October 20, 2024
Trends and Regional Differences for Fertility Preservation Procedures in Women With Breast CancerVolkan Turan, Giuliano Bedoschi, Dong-Yun Lee, et al.
JCO Precision Oncology|September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease RelapseFrédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
Cancer Treatment Reviews|January 24, 2025
Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussionStavroula L Kastora, Eirini Pantiora, Yong Hwa Hong, et al.
ESMO Open|November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trialMatteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
In Vivo (Athens, Greece)|March 4, 2022
The Margins' Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast CancerPiero Fregatti, Marco Gipponi, Giulia Atzori, et al.
International Journal of Cancer|November 15, 2019
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trialMatteo Lambertini, Francesca Poggio, Marco Bruzzone, et al.
Therapeutic Advances in Medical Oncology|September 22, 2025
Early breast cancer in young <i>BRCA</i> carriers: from diagnosis to treatment and survivorshipRoberto Borea, Luca Arecco, Simone Nardin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2024
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA studyChiara Molinelli, Marco Bruzzone, Eva Blondeaux, et al.
BMC Medicine|January 6, 2016
Cancer and fertility preservation: international recommendations from an expert meetingMatteo Lambertini, Lucia Del Mastro, Maria C Pescio, et al.
Breast (Edinburgh, Scotland)|July 15, 2018
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) studyMatteo Lambertini, Valeria Fontana, Claudia Massarotti, et al.
Pageof 38